Wat is de prijs voor Radiopharm Theranostics Limited (RAD)

Het prijs van Radiopharm Theranostics Limited (RAD) is $0.00775813

Wat is de marktkapitalisatie voor Radiopharm Theranostics Limited (RAD)

Marktkapitalisatie voorRadiopharm Theranostics Limited (RAD) is $18.35M

Radiopharm Theranostics Limited (RAD) Dividendrendement

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Jaar	Dividendrendement	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Dividendrendement

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Dividendrendement	Land
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Lonza Group AG LONN.SW	0.00%	CH
UCB S.A. UCB.BR	0.48%	BE

Bedrijf

Dividendrendement

Land